NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
6 trialsNCT02398825 2025-01-17
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT04554459 2024-08-14
Pona-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 2 Terminated
NCT03807479 2023-09-14
PONS
GWT-TUD GmbH
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01838642 2017-02-15
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated